Targeting YAP-dependent MDSC infiltration impairs tumor progression

Cancer Discovery

Volumn 6, Issue 1, 2016, Pages 80-95

  Wang, Guocan ^a   Lu, Xin ^a   Dey, Prasenjit ^a   Deng, Pingna ^a   Wu, Chia Chin ^a   Jiang, Shan ^a   Fang, Zhuangna ^a,b   Zhao, Kun ^a   Konaparthi, Ramakrishna ^a   Hua, Sujun ^a   Zhang, Jianhua ^a   Li Ni Ngtapia, Elsa M ^a   Kapoor, Avnish ^a   Wu, Chang Jiun ^a   Patel, Neelay Bhaskar ^a   Guo, Zhenglin ^a   Ramamoorthy, Vandhana ^a   Tieu, Trang N ^a   Heffernan, Tim ^a   Zhao, Di ^a   Shang, Xiaoying ^a   Khadka, Sunada ^a   Hou, Pingping ^a   Hu, Baoli ^a   Jin, Eun Jung ^a,c   Yao, Wantong ^a   Pan, Xiaolu ^a   Ding, Zhihu ^d   Shi, Yanxia ^a,b   Li, Liren ^a,b   Chang, Qing ^a   Troncoso, Patricia ^a   Logothetis, Christopher J ^a   McArthur, Mark J ^a   Chin, Lynda ^a   Alan Wang, Y ^a   Depinho, Ronald A ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c Wonkwang University   (South Korea)

^d Sanofi Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; CHEMOKINE RECEPTOR CXCR2; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMAD4 PROTEIN; TRANSCRIPTION FACTOR YAP1; CXCL5 PROTEIN, MOUSE; HIPPO PROTEIN, MOUSE; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; PTEN PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMAD4 PROTEIN, MOUSE; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL INFILTRATION; CELL MIGRATION ASSAY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MICROARRAY ANALYSIS; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PROSTATE ADENOCARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPRESSOR CELL; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; BONE MARROW CELL; DEFICIENCY; DISEASE COURSE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; CHEMOKINE CXCL5; DISEASE PROGRESSION; HUMANS; MALE; MICE; MYELOID CELLS; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; RECEPTORS, INTERLEUKIN-8B; SIGNAL TRANSDUCTION; SMAD4 PROTEIN;

EID: 84954053129     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0224     Document Type: Article

References (42)

1. Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol 2010; 7: 494-509.
2. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013; 501: 346-54.
3. Hanahan D, Coussens L. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-22.
4. Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
5. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13: 739-52.
6. Vuk-Pavlović S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al. Immunosuppressive CD14eHLA-DRlow/− monocytes in prostate cancer. Prostate 2010; 70: 443-55.
7. Idorn M, Kollgaard T, Kongsted P, Sengelov L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother 2014; 63: 1177-87.
8. Brusa D, Simone M, Gontero P, Spadi R, Racca P, Micari J, et al. Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison. Int J Urol 2013; 20: 971-8.
9. Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-Frias D, Sybert E, et al. Pten null prostate epithelium promotes localized myeloidderived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol 2014; 34: 2017-28.
10. Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, Jost TR, et al. Tumourinfiltrating Gr-1rrmyeloid cells antagonize senescence in cancer. Nature 2014; 515: 134-7.
11. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011; 470: 269-73.
12. Bjornson ZB, Nolan GP, Fantl WJ. Single-cell mass cytometry for analysis of immune system functional states. Curr Opin Immunol 2013; 25: 484-94.
13. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-802.
14. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8iiT cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172: 989-99.
15. Szuster-Ciesielska A, Hryciuk-Umer E, Stepulak A, Kupisz K, Kandefer-Szerszen M. Reactive oxygen species production by blood neutrophils of patients with laryngeal carcinoma and antioxidative enzyme activity in their blood. Acta Oncol 2004; 43: 252-8.
16. Schmielau J, Finn OJ. Activated granulocytes and granulocytederived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001; 61: 4756-60.
17. Pekarek LA, Starr BA, Toledano AY, Schreiber H. Inhibition of tumor growth by elimination of granulocytes. J Exp Med 1995; 181: 435-40.
18. Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, et al. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet 2013; 45: 739-46.
19. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet 2013; 45: 747-55.
20. Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, e t al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med 2014; 20: 676-81.
21. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-66.
22. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global doublefluorescent Cre reporter mouse. Genesis 2007; 45: 593-605.
23. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1GCD11bCCmyeloid cells that promote metastasis. Cancer Cell 2008; 13: 23-35.
24. Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, et al. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 2008; 68: 1809-19.
25. Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 2014; 13: 63-79.
26. Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 2014; 158: 185-97.
27. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014; 158: 171-84.
28. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 2012; 26: 54-68.
29. Nguyen LT, Tretiakova MS, Silvis MR, Lucas J, Klezovitch O, Coleman I, et al. ERG activates the YAP1 transcriptional program and induces the development of age-related prostate tumors. Cancer Cell 2015; 27: 797-808.
30. Kwon AT, Arenillas DJ, Worsley Hunt R, Wasserman WW. oPOSSUM-3: advanced analysis of regulatory motif over-representation across genes or ChIP-Seq datasets. G3 2012; 2: 987-1002.
31. Ding Z, Wu C-J, Jaskelioff M, Ivanova E, Kost-Alimova M, Protopopov A, et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 2012; 148: 896-907.
32. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008; 68: 927-36.
33. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-30.
34. Liu Q, Russell MR, Shahriari K, Jernigan DL, Lioni MI, Garcia FU, et al. Interleukin-1beta promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features. Cancer Res 2013; 73: 3297-305.
35. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloidderived suppressor cells infiltrating the primary tumor. PLoS Biol 2011; 9: e1001162.
36. Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 2014; 63: 1769-81.
37. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-68.
38. Osanto S, van Poppel H, Burggraaf J. Tasquinimod: a novel drug in advanced prostate cancer. Future Oncol 2013; 9: 1271-81.
39. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012; 61: 255-63.
40. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014; 1319: 47-65.
41. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4CCD25CFoxP3FFregulatory T cells. Blood 2005; 105: 4743-8.
42. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012; 149: 656-70.